Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Inventory (2016 - 2025)

Syndax Pharmaceuticals has reported Inventory over the past 9 years, most recently at $32.8 million for Q4 2025.

  • Quarterly results put Inventory at $32.8 million for Q4 2025, up 8849.18% from a year ago — trailing twelve months through Dec 2025 was $32.8 million (up 8849.18% YoY), and the annual figure for FY2025 was $32.8 million, up 8849.18%.
  • Inventory for Q4 2025 was $32.8 million at Syndax Pharmaceuticals, up from $25.0 million in the prior quarter.
  • Over the last five years, Inventory for SNDX hit a ceiling of $32.8 million in Q4 2025 and a floor of $22000.0 in Q2 2021.
  • Median Inventory over the past 3 years was $4.7 million (2025), compared with a mean of $11.5 million.
  • Biggest five-year swings in Inventory: crashed 85.03% in 2021 and later surged 8849.18% in 2025.
  • Syndax Pharmaceuticals' Inventory stood at $22000.0 in 2021, then skyrocketed by 1563.64% to $366000.0 in 2024, then surged by 8849.18% to $32.8 million in 2025.
  • The last three reported values for Inventory were $32.8 million (Q4 2025), $25.0 million (Q3 2025), and $17.7 million (Q2 2025) per Business Quant data.